Boardroom Alpha
Boardroom Alpha
MAIA · Additional Proxy Materials (DEFA14A) · Filed May 19, 2026

Maia Biotechnology Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
May 19, 2026
Ticker
MAIA
Accession
0001493152-26-024325
Boardroom Alpha · Filing insights

MAIA amends proxy to disclose CEO's brother compensation for 2025 and 2024; totals $286,321 and $242,102, aligned with industry standards.

About Maia Biotechnology Inc
Market cap
$82M
1Y TSR
−25.7%
3Y TSR
−17.0%
Board grade
C-
Sector
Healthcare
CEO
Vlad Vitoc
Last annual meeting: May 21, 2026 · View full Maia Biotechnology Inc profile →

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

(Amendment No. 1)

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement
   
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
Definitive Proxy Statement
   
Definitive Additional Materials
   
Soliciting Material under §240.14a-12

 

MAIA Biotechnology, Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

No fee required
   
Fee paid previously with preliminary materials.
   
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

 

 

 

 
 

 

MAIA Biotechnology, Inc.

Amendment and Supplement to the Proxy Statement

For the Annual Meeting of Stockholders

To be Held on May 21, 2026

 

EXPLANATORY NOTE

 

On April 7, 2026, MAIA Biotechnology, Inc. (“MAIA” or the “Company”) filed its definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission (“SEC”) for its annual meeting of shareholders to be held on June 9, 2025 (the “Annual Meeting”).

 

The Company is amending and supplementing the Proxy Statement with the information provided in this amendment and supplement to the Proxy Statement (the “Amendment and Supplement”) to update the disclosure related to compensation received in the years ended December 31, 2025 and 2024 by the brother of the Company’s Chief Executive Officer in the section entitled “CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS” in the Proxy Statement

 

Any proxies submitted by stockholders before the date of this Amendment and Supplement will be voted as instructed on those proxies, unless a stockholder changes his or her vote by submitting a later dated proxy. Stockholders should follow the instructions described in the Proxy Statement regarding how to submit proxies or vote at the Annual Meeting.

 

THIS AMENDMENT AND SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

 

This supplemental information should be read in conjunction with the Proxy Statement, which should be read in its entirety. Section references in the below disclosures are to sections in the Proxy Statement, and defined terms used but not defined herein have the meanings set forth in the Proxy Statement. To the extent the following information differs from or conflicts with the information contained in the Proxy Statement, the information set forth below shall be deemed to supersede the respective information in the Proxy Statement.

 

Amendments and Supplemental Disclosure

 

Proxy Statement

 

The section entitled “CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS” in the Proxy Statement is amended to include the disclosure below related compensation received by the brother of the Chief Executive Officer in the years ended December 31, 2025 and 2024 as follows:

 

“We paid Radu Vitoc, brother of our Chief Executive Officer Vlad Vitoc total compensation of $286,321 in the year ended December 31, 2025, consisting of $213,000 in cash and 39,000 options with a value of $73,321. In the year ended December 31, 2024, we paid Radu Vitoc total compensation of $242,102, consisting of $172,500 in cash and 50,000 options with a value of $69,602. Mr. Vitoc’s compensation in each of 2025 and 2024 was in line with industry standards.”

 

May 19, 2026

 

-2-

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Maia Biotechnology Inc (MAIA)

Reference

Frequently asked questions

When did Maia Biotechnology Inc file this DEFA14A?
Maia Biotechnology Inc (MAIA) filed this Additional Proxy Materials (DEFA14A) with the SEC on May 19, 2026. The accession number assigned by EDGAR is 0001493152-26-024325.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
MAIA amends proxy to disclose CEO's brother compensation for 2025 and 2024; totals $286,321 and $242,102, aligned with industry standards. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Maia Biotechnology Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Maia Biotechnology Inc has filed under CIK 1878313, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer